Hansa Medical, a biopharmaceutical company developing novel immunomodulatory enzymes, announced the board of directors have appointed Søren Tulstrup as new President and CEO of Hansa Medical effective from 20 March, 2018.
Hansa Medical’s acting CEO Ulf Wiinberg reverts to his former role as Chairman of Hansa Medical and Birgit Stattin Norinder reverts to her former role as member of the board of directors.
“We are pleased to welcome Søren Tulstrup as new President and CEO of Hansa Medical,” said Ulf Wiinberg, Chairman at Hansa Medical.
“Søren is an accomplished life science industry executive, who brings diverse and extensive industry experience having built and led high-performance biopharma companies, country operations and teams both in Europe and the US,” he said.
Tulstrup has a broad and extensive background as senior executive in the global biopharma industry. Recently, he served as CEO of Vifor Pharma, a Glattbrugg, Switzerland based global pharmaceutical company with a market leading position within chronic kidney disease, annual sales of approximately $1 billion and 2000 employees.
Prior to joining Vifor Pharma, he served as Senior VP, Global Franchise Head, MPS at Shire Pharmaceuticals, securing strong market performance of Elaprase, an enzyme-based treatment of the rare disease Hunter syndrome.
Tulstrup has also served as CEO of Santaris Pharma, now part of Roche, a leading clinical stage biopharmaceutical company developing RNA-targeted drugs for various therapeutic areas including cancer and rare genetic diseases.
Furthermore, Tulstrup has served in several senior commercial roles within Merck & Co. and Sandoz Pharma (Novartis) and he holds a Master of Science, Economics and Business Administration from Copenhagen Business School.
“Søren’s strong track record of managing the development, launch and growth of biopharmaceuticals globally for the treatment of rare diseases and kidney diseases greatly matches Hansa Medical’s promising position. It has been a privilege to serve as acting CEO for four months with our highly committed management team and co-workers in Lund and the US,” said Wiinberg.
